Nifedipine (Procardia, Adalat)
What studies of Nifedipine (Procardia, Adalat) found
At a glance, by condition
ME/CFS: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty): 5 findings, all C.
5 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Nifedipine (Procardia, Adalat) might help some people with ME/CFS, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Nifedipine (Procardia, Adalat) · ME/CFS is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
ME/CFS
Symptoms
Cognition (brain fog)1 study · 1 (few people) person took Nifedipine (Procardia, Adalat) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · After five days · 10 mg three times/day (few people)
Cognition (brain fog) improved.
The evidence is very uncertain about the effect of nifedipine (Procardia, Adalat) on cognition (brain fog) in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
Chronic fatigue syndrome: possible effective treatment with nifedipine. (1988)
- People in the study
- 1 in the study
- Dose
- 10 mg three times/day
- Outcome
- level of attention, mental organization, and memory retention
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Fatigue1 study · 1 (few people) person took Nifedipine (Procardia, Adalat) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · After five days · 10 mg three times/day (few people)
Fatigue improved.
The evidence is very uncertain about the effect of nifedipine (Procardia, Adalat) on fatigue in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
Chronic fatigue syndrome: possible effective treatment with nifedipine. (1988)
- People in the study
- 1 in the study
- Dose
- 10 mg three times/day
- Outcome
- excessive fatigability
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Pain1 study · 1 (few people) person took Nifedipine (Procardia, Adalat) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · After five days · 10 mg three times/day (few people)
Pain improved.
The evidence is very uncertain about the effect of nifedipine (Procardia, Adalat) on pain in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
Chronic fatigue syndrome: possible effective treatment with nifedipine. (1988)
- People in the study
- 1 in the study
- Dose
- 10 mg three times/day
- Outcome
- headache
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Daily functioning1 study · 1 (few people) person took Nifedipine (Procardia, Adalat) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · After five days · 10 mg three times/day (few people)
Daily functioning improved.
The evidence is very uncertain about the effect of nifedipine (Procardia, Adalat) on daily functioning in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
Chronic fatigue syndrome: possible effective treatment with nifedipine. (1988)
- People in the study
- 1 in the study
- Dose
- 10 mg three times/day
- Outcome
- functional status (education/work)
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Overall symptoms1 study · 1 (few people) person took Nifedipine (Procardia, Adalat) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (1 in all); not all results were tested against chance.
Studies with no comparison group1 in the study · After five days · 10 mg three times/day (few people)
Overall symptoms improved.
The evidence is very uncertain about the effect of nifedipine (Procardia, Adalat) on overall symptoms in ME/CFS. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (1 in all)
- Not all results were tested against chance
See the 1 study
-
Chronic fatigue syndrome: possible effective treatment with nifedipine. (1988)
- People in the study
- 1 in the study
- Dose
- 10 mg three times/day
- Outcome
- symptom resolution after restarting nifedipine
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
No study of this treatment alone reported side effects we could read.
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
10 to 30 mg at the start
- 2Top dose
Most often 10 mg (1 of 2 studies)
Doses across 2 studies
10 to 30 mg.
Each study’s dose, as printed
All papers
- Successful Ivabradine Use Throughout Pregnancy for Postural Orthostatic Tachycardia Syndrome: A Case Report with Reassuring Maternal-Fetal Outcomes2026 · case report · 1 in the study
Summary
This case report describes one 35-year-old gravida 2 para 1 woman with long-COVID postural orthostatic tachycardia syndrome (POTS) who had recurrent emergency department visits and cardiac intensive care admissions for orthostatic palpitations. During her second pregnancy she continued all pharmacologic therapies from preconception through delivery at 38 weeks 5 days: ivabradine 12.5 mg twice daily, propranolol 40 mg 4 times daily, midodrine 15 mg 3 times daily, methyldopa 125 mg nightly, and extended-release nifedipine 30 mg once daily. The report compares her course with her first pregnancy, when cardiac medications were discontinued. Enhanced fetal surveillance included serial nonstress testing, growth studies and fetal Dopplers. Fetal assessments were reassuring throughout gestation, with no evidence of fetal bradycardia, arrhythmia or structural abnormalities, and no evidence of sustained bradycardia or fetal growth restriction. She reported improved symptom control and functional capacity compared with her first pregnancy. At 38 weeks 5 days' gestation an elective repeat low-transverse caesarean delivery occurred without complication; a healthy female neonate was delivered with Apgar scores of 9 and 9, and cord blood gases, newborn examination and standard neonatal screening results were normal. The authors state the polypharmacy confounds attribution of outcomes solely to ivabradine and that maternal hemodynamic data are not presented.
- Chronic fatigue syndrome: possible effective treatment with nifedipine.1988 · case report · 1 in the study
Summary
This paper reports a case of a 20-year-old man with chronic fatigue syndrome. He first presented to the author with pharyngitis, periorbital edema, leg pain, and blurred vision. He was given nifedipine 10 mg three times/day; duration and route were not reported. There was no comparison group, randomisation, or crossover. After five days, his headache abated and his family noticed a marked increase in his level of attention, mental organization, and memory retention and, most prominently, no excessive fatigability. He left home without his nifedipine during a family crisis, and after three days the symptoms recurred; after restarting nifedipine the symptoms disappeared in 72 hours. On several occasions when he did not take nifedipine, symptoms returned within 72 hours. Currently, the patient is still taking nifedipine treatment and shows continued improvement. He has completed a high school general equivalency diploma, works part-time, and is currently enrolled in a junior college. Harms and withdrawals were not reported. The authors state that continuing the medication seems to prevent the symptoms, but the reason for the efficacy of nifedipine in this situation is unknown. They state that whether nifedipine's ability to ameliorate this patient's symptoms can be duplicated in other patients with the chronic fatigue syndrome will depend on further clinical trials.